...
gnft-img

Genfit, Common Stock

GNFT

NSQ

$3.79

+$0.13

(3.55%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$182.66M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
9.3846
Volume info-icon
This is the total number of shares traded during the most recent trading day.
54.33K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.12
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.31 L
$6.42 H
$3.79

About Genfit, Common Stock

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGNFTSectorS&P500
1-Week Return-1.04%-2.06%-0.55%
1-Month Return-13.27%-1.92%2.72%
3-Month Return-12.67%-10.4%7.66%
6-Month Return-8.67%-4.6%10.15%
1-Year Return-3.32%4.06%27.53%
3-Year Return-32.92%1.94%32.31%
5-Year Return-77.43%36.48%89.2%
10-Year Return-82.9%97.46%194.59%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue30.84M765.00K80.07M20.20M28.57M[{"date":"2019-12-31","value":38.52,"profit":true},{"date":"2020-12-31","value":0.96,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":25.22,"profit":true},{"date":"2023-12-31","value":35.68,"profit":true}]
Cost of Revenue-202.00K161.00K248.00K341.00K[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":59.24,"profit":true},{"date":"2021-12-31","value":47.21,"profit":true},{"date":"2022-12-31","value":72.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit30.84M563.00K79.91M19.95M28.22M[{"date":"2019-12-31","value":38.59,"profit":true},{"date":"2020-12-31","value":0.7,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":24.96,"profit":true},{"date":"2023-12-31","value":35.32,"profit":true}]
Gross Margin100.00%73.59%99.80%98.77%98.81%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":73.59,"profit":true},{"date":"2021-12-31","value":99.8,"profit":true},{"date":"2022-12-31","value":98.77,"profit":true},{"date":"2023-12-31","value":98.81,"profit":true}]
Operating Expenses88.67M78.35M48.11M47.50M54.80M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":88.37,"profit":true},{"date":"2021-12-31","value":54.26,"profit":true},{"date":"2022-12-31","value":53.56,"profit":true},{"date":"2023-12-31","value":61.81,"profit":true}]
Operating Income(57.83M)(77.79M)76.74M(27.55M)(26.58M)[{"date":"2019-12-31","value":-75.36,"profit":false},{"date":"2020-12-31","value":-101.37,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.9,"profit":false},{"date":"2023-12-31","value":-34.64,"profit":false}]
Total Non-Operating Income/Expense(16.39M)(37.50M)30.39M6.91M(3.35M)[{"date":"2019-12-31","value":-53.93,"profit":false},{"date":"2020-12-31","value":-123.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":22.73,"profit":true},{"date":"2023-12-31","value":-11.03,"profit":false}]
Pre-Tax Income(65.72M)(101.65M)69.47M(23.84M)(28.51M)[{"date":"2019-12-31","value":-94.6,"profit":false},{"date":"2020-12-31","value":-146.31,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-34.31,"profit":false},{"date":"2023-12-31","value":-41.04,"profit":false}]
Income Taxes(576.00K)(428.00K)2.21M(116.00K)380.00K[{"date":"2019-12-31","value":-26,"profit":false},{"date":"2020-12-31","value":-19.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-5.24,"profit":false},{"date":"2023-12-31","value":17.16,"profit":true}]
Income After Taxes(65.14M)(101.22M)67.26M(23.72M)(28.89M)[{"date":"2019-12-31","value":-96.86,"profit":false},{"date":"2020-12-31","value":-150.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.27,"profit":false},{"date":"2023-12-31","value":-42.96,"profit":false}]
Income From Continuous Operations(65.14M)(101.22M)67.26M(23.72M)(28.89M)[{"date":"2019-12-31","value":-96.86,"profit":false},{"date":"2020-12-31","value":-150.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.27,"profit":false},{"date":"2023-12-31","value":-42.96,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(65.14M)(101.22M)67.26M(23.72M)(28.89M)[{"date":"2019-12-31","value":-96.86,"profit":false},{"date":"2020-12-31","value":-150.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-35.27,"profit":false},{"date":"2023-12-31","value":-42.96,"profit":false}]
EPS (Diluted)-(3.25)-0.11-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2881.99,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GNFT
Cash Ratio 1.69
Current Ratio 3.74
Quick Ratio 3.74

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GNFT
ROA (LTM) 6.51%
ROE (LTM) 25.91%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GNFT
Debt Ratio Lower is generally better. Negative is bad. 0.50
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.50

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GNFT
Trailing PE 9.38
Forward PE 7.27
P/S (TTM) 2.27
P/B 1.85
Price/FCF NM
EV/R 2.43
EV/Ebitda 6.44

FAQs

What is Genfit share price today?

Genfit (GNFT) share price today is $3.79

Can Indians buy Genfit shares?

Yes, Indians can buy shares of Genfit (GNFT) on Vested. To buy Genfit from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GNFT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Genfit be purchased?

Yes, you can purchase fractional shares of Genfit (GNFT) via the Vested app. You can start investing in Genfit (GNFT) with a minimum investment of $1.

How to invest in Genfit shares from India?

You can invest in shares of Genfit (GNFT) via Vested in three simple steps:

  • Click on Sign Up or Invest in GNFT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Genfit shares
What is Genfit 52-week high and low stock price?

The 52-week high price of Genfit (GNFT) is $6.42. The 52-week low price of Genfit (GNFT) is $3.31.

What is Genfit price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Genfit (GNFT) is 9.3846

What is Genfit price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Genfit (GNFT) is 1.85

What is Genfit dividend yield?

The dividend yield of Genfit (GNFT) is 0.00%

What is the Market Cap of Genfit?

The market capitalization of Genfit (GNFT) is $182.66M

What is Genfit’s stock symbol?

The stock symbol (or ticker) of Genfit is GNFT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top